focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMTPH.L Regulatory News (MTPH)

  • There is currently no data for MTPH

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES

23 Mar 2015 10:43

RNS Number : 1618I
Midatech Pharma PLC
23 March 2015
 

 

For filings with the FCA include the annex

For filings with issuer exclude the annex

TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuerof existing shares to which voting rights areattached: ii

Midatech Pharma PLC

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

X

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to thenotification obligation: iii

Arrowgrass Capital Partners LLP

4. Full name of shareholder(s)  (if different from 3.):iv

Arrowgrass Master Fund Limited

5. Date of the transaction and date onwhich the threshold is crossed orreached: v

20 March 2015

6. Date on which issuer notified:

23 March 2015

7. Threshold(s) that is/are crossed orreached: vi, vii

5%

 

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type ofshares

if possible usingthe ISIN CODE

Situation previousto the triggeringtransaction

Resulting situation after the triggering transaction

NumberofShares

NumberofVotingRights

Numberof shares

Number of votingrights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

 

 

GB00BRTL9B63

1,469,500

1,469,500

1,379,500

1,379,500

4.96%

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financialinstrument

Expirationdate xiii

Exercise/Conversion Period xiv

Number of votingrights that may beacquired if theinstrument isexercised/ converted.

% of votingrights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financialinstrument

Exercise price

Expiration date xvii

Exercise/Conversion period xviii

Number of voting rights instrument refers to

 

% of voting rights xix, xx

 

 

 

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

1,379,500

4.96%

 

9. Chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held, if applicable: xxi

 

 

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will ceaseto hold:

12. Date on which proxy holder will cease to holdvoting rights:

13. Additional information:

14. Contact name:

Matthew Tonge

15. Contact telephone number:

02031001055

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLBXLFLEXFZBBF
Date   Source Headline
27th Feb 20194:40 pmRNSSecond Price Monitoring Extn
27th Feb 20194:35 pmRNSPrice Monitoring Extension
27th Feb 201910:52 amRNSHolding(s) in Company
26th Feb 201911:26 amRNSFinalisation of Licence Agreement
25th Feb 201912:23 pmRNSResult of the General Meeting and Board changes
8th Feb 20194:39 pmRNSPosting of Circular and Notice of General Meeting
4th Feb 20196:32 pmRNSResult of Placing
4th Feb 20193:16 pmRNSProposed Placing and Open Offer
29th Jan 20199:23 amRNSStrategic Investment & Licence Agreement
25th Jan 20197:00 amRNSFDA feedback on clinical plan for MTD201
15th Jan 20191:56 pmRNSHolding(s) in Company
15th Jan 20199:36 amRNSHolding(s) in Company
11th Jan 201910:58 amRNSHolding(s) in Company
10th Jan 201911:15 amRNSMidatech announces EUR 1.5 million loan facility
20th Dec 20187:00 amRNSCorporate update and potential fundraise
20th Dec 20187:00 amRNSMidatech Announces Microsphere Partnership
28th Nov 20181:17 pmRNSHolding(s) in Company
20th Nov 201812:59 pmRNSHolding(s) in Company
5th Nov 20189:55 amRNSHolding(s) in Company
1st Nov 20185:48 pmRNSNASDAQ Minimum Bid Price Extension
1st Nov 20187:00 amRNSCompletion of Midatech Pharma US Sale
15th Oct 201812:17 pmRNSResult of General Meeting
28th Sep 201810:04 amRNSPosting of Circular and Notice of General Meeting
27th Sep 20187:01 amRNSInterim Results
27th Sep 20187:00 amRNSProposed Sale of Midatech Pharma US Inc
6th Sep 20187:00 amRNSNotice of Interim Results
31st Aug 20187:00 amRNSInterim results from MTD201 exploratory study
1st Aug 20187:00 amRNSIssue of Equity for Midatech Share Incentive Plan
25th Jul 20187:00 amRNSTrading Update
23rd Jul 20187:00 amRNSUS Co-Promotion Agreement
27th Jun 201810:56 amRNSResult of AGM
8th Jun 20187:00 amRNSMidatech US enrols patient in Gelclair trial
1st Jun 20187:00 amRNSBoard change
1st Jun 20187:00 amRNS2017 Annual Report and AGM Notification
25th May 20187:00 amRNSMidatech commences US clinical study with MTX110
21st May 20187:00 amRNSMidatech commences dosing in equivalence study
8th May 20187:00 amRNSSEC filing regarding share price movement
3rd May 201812:15 pmRNSMidatech Announces Receipt of NASDAQ Notice
3rd May 20187:00 amRNSStmnt re Share Price Movement
2nd May 20184:40 pmRNSSecond Price Monitoring Extn
2nd May 20184:35 pmRNSPrice Monitoring Extension
23rd Apr 20187:00 amRNSFinancial results for year ended 31 December 2017
9th Apr 20188:25 amRNSNotice of Results
15th Mar 20187:00 amRNSChanges in Senior Management Team
28th Feb 20187:00 amRNSMidatech gets Orphan Drug Designation for MTD119
14th Feb 20187:00 amRNSTrading Update
16th Jan 20187:00 amRNSIND approval for DIPG treatment MTX110
9th Jan 20187:00 amRNSQ-Octreotide first in-human EU study approved
3rd Jan 20181:36 pmRNSHolding(s) in Company
2nd Jan 20187:00 amRNSMidatech Loan Agreement with MidCap Financial

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.